Pharmaceutical intermediates
Rivaroxaban Intermediates
7 pharmaceutical intermediates for Rivaroxaban. Indication: Pulmonary Embolism; Stroke; Congenital Heart Defect; Thrombosis; Coronary Artery Disease; Coronary Artery Lesion; Peripheral Arterial Disease; Atherosclerosis; Venous Thrombosis; Embolism; Venous Thromboembolism.
About Rivaroxaban
- Originator
- Bayer Healthcare Pharmaceuticals Inc.; Johnson & Johnson Pharmaceutical Research & Development Llc
- Indication
- Pulmonary Embolism; Stroke; Congenital Heart Defect; Thrombosis; Coronary Artery Disease; Coronary Artery Lesion; Peripheral Arterial Disease; Atherosclerosis; Venous Thrombosis; Embolism; Venous Thromboembolism
- Approved Date
- 09/30/2008
- DS/DP
- 08/28/2024
Available intermediates
7 intermediates currently listed for Rivaroxaban. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-(4-Aminophenyl)morpholin -3-one | 438056-69-0 | / | / |
| (S)-(+)-N-(2,3-Epoxypropyl)phthalimide | 161596-47-0 | / | / |
| 5-Chlorothiophene-2-carboxylic acid | 24065-33-6 | / | / |
| 5-Chlorothiophene-2-carbonyl chloride | 42518-98-9 | / | / |
| 2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione | 446292-08-6 | / | / |
| 4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride | 898543-06-1 | / | / |
| 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione | 446292-07-5 | / | / |
Other programs under R
Building toward Rivaroxaban?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →